Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer.

Autor: Graybill WS; Division of Gynecologic Oncology, Medical University of South Carolina, Charleston, SC 29425, USA., Vergote I; University Hospitals Leuven, Leuven Cancer Institute, and Belgium & Luxembourg Gynaecological Oncology Group (BGOG), Leuven, B912 3000, Belgium., Pothuri B; GOG Foundation and Laura & Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY 10016, USA., Anttila M; Kuopio University Hospital, Kuopio, Finland, and NSGO, Copenhagen, 9 70200, Denmark., O'Malley DM; The Ohio State University andthe James Comprehensive Cancer Center, Columbus, OH 43210, USA., Lorusso D; Humanitas San Pio X, Milan, Humanitas University, Rozzano, 20089, Italy., Haggerty AF; Hackensack Meridian Health, Hackensack, NJ 07601, USA., Fabbro M; Institut Régional du Cancer de Montpellier, Montpellier, and GINECO, Paris, 34298, France., Chan JK; California Pacific Medical Center Palo Alto Medical Foundation, Sutter Cancer Research Consortium, San Francisco, CA 94301, USA., Heitz F; AGO Study Group and Kliniken Essen-Mitte, Essen, and Charité - Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Department of Gynaecology, Berlin, 12203, Germany., Willmott LJ; Arizona Center for Cancer Care, Phoenix, AZ 85027, USA., Bruchim I; Hillel Yaffe Medical Center, Hadera, Technion Institute of Technology, Haifa, 38100, Israel, & ISGO., Zhuo Y; Kadlec Hematology and Oncology Clinic, Richland, WA 99336, USA., Estévez-García P; Hospital Universitario Virgen del Rocío, Sevilla, and GEICO, Madrid, 41013, Spain., Monk BJ; GOG Foundation; Florida Cancer Specialists and Research Institute, West Palm Beach, FL 33401, USA., Denys H; Ghent University Hospital, Ghent, 9000, Belgium., Knudsen A; Odense University Hospital, Odense, 5000, Denmark., Tinker AV; BC Cancer Vancouver, and Department of Medicine, University of British Columbia, Vancouver, BC, V6T1Z1, Canada., Sánchez LM; Hospital Universitario 12 de Octubre & GEICO, Madrid, 28041, Spain., Provencher D; Centre Hospitalier de l'Université de Montréal, Université de Montréal and Institut du Cancer de Montréal, Montreal, QC, H3T1J4, Canada., Barretina-Ginesta MP; Medical Oncology Department, Institut Català d'Oncologia; Girona Biomedical Research Institute (IDIBGI-CERCA), Girona University, Girona, Spain, and GEICO, 08908, Spain., Hartman J; GSK, Philadelphia, PA 19112, USA., Booth DV; GSK, Durham, NC 27709, USA., González-Martín A; Medical Oncology Department, Program in Solid Tumours, CIMA, Cancer Center Clínica Universidad de Navarra, Madrid, and Grupo Español de Investigación en Cancer ginecológicO (GEICO), Madrid, 28027, Spain.

Publikováno v: Journal of comparative effectiveness research [J Comp Eff Res] 2025 Jan; Vol. 14 (1), pp. e240133. Date of Electronic Publication: 2024 Dec 06.